News
Company News: Curetis Launches Unyvero LRT Panel for BAL Specimens in the U.S.
— Panel also includes atypical pathogens such as Pneumocystis jirovecii
— LRT BAL Panel expected to substantially increase total addressable market for Unyvero System in the U.S.
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the U.S. launch of its Unyvero LRT BAL Lower Respiratory Tract Application Cartridge for use with bronchoalveolar lavage (BAL) samples to diagnose lower respiratory tract infections such as pneumonia. Read more…
Company News: Curetis Receives U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens
— Broad Unyvero LRT BAL panel also includes atypical pathogens such as Pneumocystis jirovecii
— Clearance expected to substantially increase total addressable market for Unyvero System in the U.S.
— Commercial launch in the U.S. expected for Q1-2020
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market its Unyvero LRT Lower Respiratory Tract Application Cartridge for use with bronchoalveolar lavage (BAL) samples to diagnose lower respiratory tract infections such as pneumonia.
Company News: Aleva Neurotherapeutics Receives CE Mark for its directSTIM™ Deep Brain Stimulation System and Raises USD 8 Million Private Equity
Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor, today announced that it has been awarded the CE Mark for its flagship product, the directSTIMTM Deep Brain Stimulation System.
Company News: ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
ImmunOs Therapeutics AG, a Swiss bio-technology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A financing of CHF 15 million. The round was co-led by the Basel life sciences venture capital firm BioMedPartners and Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), with the participation of Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd alongside new private and existing investors.